Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of "Hold" from Brokerages

Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has been assigned an average recommendation of "Hold" from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.75.

INZY has been the subject of a number of analyst reports. Jefferies Financial Group restated a "hold" rating and set a $4.00 price objective (down previously from $15.00) on shares of Inozyme Pharma in a research report on Friday. Raymond James cut their target price on Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 12th. Needham & Company LLC downgraded Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research note on Friday. Wedbush downgraded Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research note on Friday. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and set a $4.00 target price on shares of Inozyme Pharma in a research note on Friday.

Institutional Trading of Inozyme Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of INZY. Affinity Asset Advisors LLC raised its stake in shares of Inozyme Pharma by 40.7% in the 4th quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company's stock worth $11,003,000 after buying an additional 1,150,000 shares in the last quarter. Sanofi bought a new stake in shares of Inozyme Pharma in the 4th quarter worth $1,228,000. Renaissance Technologies LLC raised its stake in shares of Inozyme Pharma by 155.7% in the 4th quarter. Renaissance Technologies LLC now owns 421,399 shares of the company's stock worth $1,167,000 after buying an additional 256,599 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Inozyme Pharma in the 4th quarter worth $658,000. Finally, Pale Fire Capital SE raised its stake in shares of Inozyme Pharma by 101.7% in the 1st quarter. Pale Fire Capital SE now owns 440,807 shares of the company's stock worth $401,000 after buying an additional 222,270 shares in the last quarter. Institutional investors own 88.30% of the company's stock.

Inozyme Pharma Stock Performance

Shares of NASDAQ INZY traded down $0.04 during mid-day trading on Thursday, hitting $3.95. The company had a trading volume of 6,338,690 shares, compared to its average volume of 797,776. Inozyme Pharma has a 12 month low of $0.72 and a 12 month high of $6.24. The stock has a market cap of $255.02 million, a price-to-earnings ratio of -2.53 and a beta of 1.35. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. The firm's 50 day simple moving average is $1.21 and its two-hundred day simple moving average is $1.87.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). As a group, equities research analysts forecast that Inozyme Pharma will post -1.59 earnings per share for the current year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.